Table 2.

Possible reasons for nonacceleration in patients with Clinical Disease Activity Index (CDAI) score >10 in the treat‐to‐target study arm^a

Reasonb	All visits, month no.c					Visits without treatment acceleration in prior 3 months, month no.c
	1–3 (n = 150)	4–6 (n = 98)	7–9 (n = 70)	10–12+ (n = 69)d	Overall	1–3 (n = 48)	4–6 (n = 42)	7–9 (n = 30)	10–12+ (n = 45)d	Overall
Medication response time lag	68.0	56.1	48.6	21.7	53.2	39.6	38.1	26.7	13.3	29.7
Patient preference	24.7	28.6	38.6	52.2	33.1	50.0	38.1	53.3	53.3	52.1
Comorbid conditions	6.7	8.2	5.7	5.8	6.7	8.3	11.9	6.7	4.4	7.9
Disagree with CDAI	2.7	10.2	5.7	11.6	6.7	2.1	11.9	10.0	11.1	8.5
Surgery	2.7	1.0	5.7	7.3	3.6	4.2	2.4	13.3	6.7	6.1
Nonrheumatoid arthritis pain	0	1.0	0	4.4	1.0	0	0	0	2.2	0.6
Pregnancy	0	1.0	1.4	2.9	1.0	0	0	0	2.2	0.6
Tuberculosis	0	0.0	0	1.5	0.3	0	0	0	2.2	0.6

^aValues are percentages. Possible reasons for nonacceleration were a new or worsening comorbid condition, anticipated medication response time lag (e.g., time for the medication to have the maximal effect was inadequate), physician disagreement with CDAI score (considered the patient as not having moderate/high disease activity), nonrheumatoid arthritis pain was influencing the disease activity measure, recent or pending surgical procedure, pregnancy, breastfeeding, or planning to become pregnant, history or new diagnosis of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus, history of positive tuberculin test or equivalent or had not received treatment for latent tuberculosis, and patient preference.

^bMore than 1 reason could be reported.

^cNumber of visits with a CDAI score >10.

^dThe 10–12+ month group includes visits that occurred after 12 months.